Peripherally selective drugs have their primary mechanism of action outside of the central nervous system (CNS), usually because they are excluded from the CNS by the blood–brain barrier. By being excluded from the CNS, drugs may act on the rest of the body without producing side-effects related to their effects on the brain or spinal cord. For example, most opioids cause sedation when given at a sufficiently high dose, but peripherally selective opioids can act on the rest of the body without entering the brain and are less likely to cause sedation.[1] These peripherally selective opioids can be used as antidiarrheals, for instance loperamide (Imodium).[2]
Mechanisms of peripheral selectivity include physicochemical hydrophilicity and large molecular size, which prevent drug permeation through the lipid bilayer cell membranes of the blood–brain barrier, and efflux out of the brain by blood–brain barrier transporters such as P-glycoprotein among many others.[2][3][4] Transport out of the brain by P-glycoprotein is thought to be responsible for the peripheral selectivity of many drugs, including loperamide, domperidone, fexofenadine, bilastine, cetirizine, ivermectin, and dexamethasone, among others.[2][5][6][7][8]
Examples
edit- α-Methylserotonin – a serotonin receptor agonist
- Alvimopan – a μ-opioid receptor antagonist used in the treatment of postoperative ileus
- Anastrozole – an aromatase inhibitor used in the treatment of breast cancer
- Atenolol – a beta blocker
- Benserazide – an aromatic L-amino acid decarboxylase inhibitor used in combination with levodopa in the treatment of Parkinson's disease
- Bethanechol – a muscarinic acetylcholine receptor agonist used in the treatment of dry mouth and urinary retention
- Bicalutamide – an antiandrogen with peripheral selectivity in animals but seemingly not in humans
- Bilastine – a non-sedating antihistamine
- Bisoprolol – a beta blocker
- Carbachol – a non-selective acetylcholine receptor agonist used in the treatment of glaucoma
- Carbidopa – an aromatic L-amino acid decarboxylase inhibitor used in combination with levodopa in the treatment of Parkinson's disease
- Carteolol – a beta blocker
- Cetirizine – a non-sedating antihistamine
- Colchicine – an alkaloid and tubulin polymerization inhibitor used to treat gout
- Darolutamide – an antiandrogen used in the treatment of prostate cancer
- Desloratadine – a non-sedating antihistamine
- Dexamethasone – a glucocorticoid with some peripheral selectivity
- Digoxin – a cardiac glycoside and sodium–potassium pump inhibitor
- Domperidone – a D2 receptor antagonist used as an antiemetic, gastroprokinetic agent, and galactogogue
- Dopamine – a dopamine receptor agonist used as a cardiac stimulant and positive inotropic agent
- Eluxadoline – a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist used in the treatment of diarrhea-predominant irritable bowel syndrome
- Entacapone – a catechol-O-methyltransferase inhibitor used in combination with levodopa in the treatment of Parkinson's disease[9]
- Epinephrine (adrenaline) – an adrenergic receptor agonist used as a cardiac stimulant and in the treatment of anaphylaxis
- Esmolol – a beta blocker
- Fenoldopam – a D1 receptor agonist used as an antihypertensive agent
- Fexofenadine – a non-sedating antihistamine
- Fulvestrant – an antiestrogen used in the treatment of breast cancer
- GABA – a dietary supplement
- Glycopyrronium bromide – an anticholinergic
- Hyoscine butylbromide – an anticholinergic
- Itopride – a D2 receptor antagonist and acetylcholinesterase inhibitor used as a gastroprokinetic agent
- Ivermectin – an antiparasitic
- Labetalol – a beta blocker
- Levocetirizine – a non-sedating antihistamine
- Loperamide – a μ-opioid receptor agonist used as an antidiarrheal
- Loratadine – a non-sedating antihistamine
- Methacholine – a choline ester and muscarinic acetylcholine receptor agonist
- Methylhomatropine – an anticholinergic
- Methylnaltrexone – a μ-opioid receptor antagonist used in the treatment of opioid-induced constipation
- Metopimazine – a D2 receptor antagonist used in the treatment of nausea, vomiting, and gastroparesis
- Midodrine – an α1-adrenergic receptor agonist used in the treatment of orthostatic hypotension
- Nadolol – a beta blocker
- Naloxegol – a μ-opioid receptor antagonist used in the treatment of opioid-induced constipation
- Norepinephrine (noradrenaline) – an adrenergic receptor agonist
- Ondansetron – a 5-HT3 receptor antagonist with some peripheral selectivity
- Opicapone – a catechol-O-methyltransferase inhibitor used in combination with levodopa in the treatment of Parkinson's disease[10]
- Peptides and proteins (e.g., insulin, oxytocin, vasopressin, opioid peptides, growth factors, many others)
- Pirenzepine – an anticholinergic
- Pyridostigmine – an acetylcholinesterase inhibitor and parasympathomimetic
- Serotonin – a serotonin receptor agonist
- Sotalol – a beta blocker
- Terfenadine – a non-sedating antihistamine
- Timepidium bromide – an anticholinergic
- Tolcapone – a catechol-O-methyltransferase inhibitor used in combination with levodopa in the treatment of Parkinson's disease[11]
- Trimetaphan camsilate – a nicotinic acetylcholine receptor antagonist
- Trospium chloride – an anticholinergic
- Tyramine – a norepinephrine–dopamine releasing agent and sympathomimetic agent[12][13]
- Vinblastine – a Vinca alkaloid and antineoplastic agent
References
edit- ^ Stein, C; Zöllner, C (2009). "Opioids and Sensory Nerves". Sensory Nerves. Handbook of Experimental Pharmacology. Vol. 194. pp. 495–518. doi:10.1007/978-3-540-79090-7_14. ISBN 978-3-540-79089-1. PMID 19655116.
- ^ a b c Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Adv Drug Deliv Rev. 36 (2–3): 179–194. doi:10.1016/s0169-409x(98)00085-4. PMID 10837715.
- ^ Dyrna F, Hanske S, Krueger M, Bechmann I (September 2013). "The blood-brain barrier". J Neuroimmune Pharmacol. 8 (4): 763–73. doi:10.1007/s11481-013-9473-5. PMID 23740386. S2CID 255272031.
- ^ Terasaki T, Ohtsuki S (January 2005). "Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology". NeuroRx. 2 (1): 63–72. doi:10.1602/neurorx.2.1.63. PMC 539321. PMID 15717058.
- ^ Schinkel AH, Wagenaar E, Mol CA, van Deemter L (June 1996). "P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs". J Clin Invest. 97 (11): 2517–24. doi:10.1172/JCI118699. PMC 507337. PMID 8647944.
- ^ De Kloet ER (October 1997). "Why Dexamethasone Poorly Penetrates in Brain". Stress. 2 (1): 13–20. doi:10.3109/10253899709014734. PMID 9787252.
- ^ Church, Martin K. (2021). "Antihistamines". Urticaria and Angioedema. Springer International Publishing. pp. 153–165. doi:10.1007/978-3-030-84574-2_11. ISBN 978-3-030-84573-5. S2CID 239944965.
- ^ Hu Y, Sieck DE, Hsu WH (October 2015). "Why are second-generation H1-antihistamines minimally sedating?". Eur J Pharmacol. 765: 100–6. doi:10.1016/j.ejphar.2015.08.016. PMID 26291661.
- ^ Habet S (August 2022). "Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer". Int J Neuropsychopharmacol. 25 (7): 567–575. doi:10.1093/ijnp/pyac021. PMC 9352175. PMID 35302623.
Entacapone is a potent and specific peripheral catechol-O-methyltransferase inhibitor. [...] Entacapone has no antiparkinsonian activity as a sole agent. Therefore, it must be given as an adjunct to LD and a peripherally acting DDC inhibitor, such as carbidopa. Entacapone acts peripherally and does not penetrate the blood-brain barrier (BBB). [...] It is poorly lipophilic and does not penetrate the BBB to any significant extent. Its clinical effects are thus due to peripheral COMT inhibition only (Nutt, 1998; Fahn et al, 2004). [...] Entacapone is poorly lipophilic. Therefore, its clinical effects are due to peripheral COMT inhibition alone. [...] Entacapone is a potent, specific, and reversible COMT inhibitor. The drug has been shown to act peripherally, but not centrally, when given at clinically effective doses.
- ^ Fabbri M, Rosa MM, Ferreira JJ (October 2016). "Clinical pharmacology review of opicapone for the treatment of Parkinson's disease". Neurodegener Dis Manag. 6 (5): 349–62. doi:10.2217/nmt-2016-0022. PMID 27599671.
Opicapone (OPC) is a novel, long-acting, peripherally selective, once daily, third-generation catechol-O-methyl transferase inhibitor.
- ^ Keating GM, Lyseng-Williamson KA (2005). "Tolcapone: a review of its use in the management of Parkinson's disease". CNS Drugs. 19 (2): 165–184. doi:10.2165/00023210-200519020-00006. PMID 15697329.
The efficacy of tolcapone as an adjunct to levodopa in patients with Parkinson's disease has primarily been attributed to its ability to inhibit peripheral it is thought that tolcapone enters the CNS to a minimal extent only.[16] However, results [17] of a study in patients with Parkinson's disease, as well as results of animal studies,[18-21] suggest that tolcapone also has central activity.
- ^ Gillman PK (November 2018). "A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths". J Neural Transm (Vienna). 125 (11): 1707–1717. doi:10.1007/s00702-018-1932-y. PMID 30255284.
- ^ Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
External links
edit- Media related to Peripherally selective drugs at Wikimedia Commons